Bezlotoxumab

CHEMBL2108670 Phase 4 Approved Antibody

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

A monoclonal antibody that neutralizes one of the two toxins produced by Clostridioides difficile bacteria, helping to prevent recurrent C. difficile infections. It is used alongside standard antibiotic treatment in adults at high risk for recurrence. It does not treat the active infection itself but reduces the chance of it coming back.

Therapeutic Areas

Infectious Disease

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

A monoclonal antibody that neutralizes one of the two toxins produced by Clostridioides difficile bacteria, helping to prevent recurrent C. difficile infections. It is used alongside standard antibiotic treatment in adults at high risk for recurrence. It does not treat the active infection itself but reduces the chance of it coming back.

Yes, Bezlotoxumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2108670. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

PillFYI

Looking for patient-friendly information?

Bezlotoxumab on PillFYI

Quick Data

Synonyms: 1

External Links

ChEMBL CHEMBL2108670

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.